Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
115Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $63.36B | $12.88B | $2.02 |
| 2024 | $62.40B | $8.28B | $1.30 |
| 2023 | $60.44B | $11.50B | $1.80 |
| 2022 | $65.81B | $12.42B | $1.94 |
| 2021 | $62.80B | $13.93B | $2.05 |
Social Signal Score
Earnings
Thu, Feb 4(in 6 months)
Consensus estimate $1.49 per share
Typical surprise +0.9% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$1.66 vs $1.58beat
- Thu, Jan 29$1.36 vs $1.35beat
- Thu, Jul 24$1.74 vs $1.62beat
- Thu, Jan 30$1.18 vs $1.17beat
- Mon, Jul 22$1.43 vs $1.30beat
- Thu, Feb 1$1.23 vs $1.22beat
Estimates and results for RHHBY via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
Project earnings forward and see what return today's price implies.
Seeded from RHHBY's reported EPS growth of -0.4% a year over 4 years.
- EPS in 5 years
- $1.97
- Implied price
- $39.31
- Return from $54.52
- -6.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $19.55 — -64.1% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 14 | 17 | 20 | 23 | 26 |
|---|---|---|---|---|---|
| -10.4% | -21.5% | -18.4% | -15.7% | -13.3% | -11.2% |
| -5.4% | -17.2% | -13.9% | -11.0% | -8.5% | -6.2% |
| -0.4% | -12.8% | -9.3% | -6.3% | -3.7% | -1.3% |
| 4.6% | -8.4% | -4.8% | -1.6% | 1.2% | 3.7% |
| 9.6% | -4.0% | -0.2% | 3.1% | 6.0% | 8.6% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Mentions (1)
- Newsseekingalpha.com·2d ago·Positive
Roche Is Getting More Benefit Of The Doubt On Improving Execution Roche Holding AG remains a respectable long-term hold, supported by a deep pipeline, strong execution, and robust financial resources. Q2 results showed 5% revenue growth and better-than-expected operating margin, validating management's focus on R&D efficiency and cost control. Key upcoming clinical readouts in oncology, immunology, and hematology could drive meaningful revenue shifts over the next 12–24 months.
View source ↗